Navigation Links
Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
Date:12/10/2010

DALLAS and NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.  Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date.  The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.

"In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs," stated Jeffrey B. Davis, President & CEO.  He continued, "This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward."

Hudson Securities, Inc., a subsidiary of Hudson Holding Corporation (OTC Bulletin Board: HDHL), acted as the Company's placement agent in connection with the offering. The common stock and warrants are being offered by Access pursuant to an effective registration statement(s) on Form S-1 filed with the Securities and Exchange Commission ("SEC").

This press rele
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
4. Dynamic Ventures Corporations Information To Be Available Through Standard & Poors Market Access Program
5. Castle Access Names New Managing Director
6. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
7. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
8. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
11. Orchestrall Sponsors China Business Toolbox: Brings Focus to the How and When of China Market Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... China, Aug. 18 /PRNewswire-FirstCall/,-- MicuRx Pharmaceuticals, ... antibiotics, today announced the nomination of,MRX- ... candidate. MRX-I is an,antibacterial molecule targeting ... aureus (MRSA).,Simultaneously, the company expanded its ...
... Drug Target Knowledge Databases ... Related to Nuclear Receptors and Proteases, PARIS, August ... solutions that accelerate life sciences discovery,announced today the release ... include knowledge databases for the important,drug targets Nuclear Receptor ...
... Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ... of China,("PRC"), today announced financial results for the quarter and ... Highlights -- Total revenues increased to $19.4 million, up ... 2007 -- Gross profit was $9.7 million, up 76.4% ...
Cached Biology Technology:MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China 2Aureus Pharma Releases New Unified Knowledge Database 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/18/2014)... In a sample of patients with undiagnosed, suspected genetic ... associated with a higher molecular diagnostic yield than traditional ... JAMA . The study is being released to ... meeting. , Exome sequencing, which sequences the protein­coding region ... genetic material present in a cell or organism), has ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
ANTI PIG LDH H4...
... in refrigerators, freezers, or liquid nitrogen. Conveniently sized to ... color coding to project, user, lab, etc. Holes in ... air circulation. Supplied with 10 x 10 (11.6 mm ... dimensions: 13 x 13 x 5.1 cm H (5 ...
Recombinant Rhesus Monkey IFN-Alpha...
RABBIT ANTI AMPHOTERIN...
Biology Products: